Summary In the present multicentre randomized phase 11 trial, the activity and toxicity of three platinum-based combination regimens for the treatment of advanced non-small-cell lung cancer (NSCLC) were evaluated. The three regimens were: MVP (mitomycin-C 6 mg m-2 on day 1, vindesine 3 mg m-2 on days 1 and 15, and cisplatin 80 mg m-2 on day 1 every 28 days), PIN (cisplatin 80 mg m-2 day 1, ifosfamide 3 g m-2 day 1 and vinorelbine 25 mg m-2 day 1 and 8 every 21 days) and CaN (carboplatin 350 mg m-2 day 1 and vinorelbine 25 mg m-2 days 1 and 8 every 28 days). A total of 140 chemotherapy-naive patients entered the study; 49 patients were treated with MVP, 48 with PIN and 43 with CaN. Sixty-seven per cent of the patients had stage IV disease. Response rates, calculated on an 'intention to treat' basis, were as follows: MVP, 14.3% (95% Cl 5.94-27.2%); PIN, 16.7% (95% Cl 7.4-30.2%); and CaN, 14% (95% Cl 5.3-27.9%). The overall median survivals were 256, 269 and 243 days for patients treated with MVP, PIN and CaN respectively. Myelosuppression was the most frequent toxicity: grade 3-4 leucopenia was observed in 14.3%, 25% and 18.6% of patients treated with MVP, PIN and CaN respectively. This multicentre phase 11 randomized trial shows that MVP, PIN and CaN can be administered on an outpatient basis with acceptable toxicities. Unfortunately, the three regimens showed an activity significantly lower than that reported in previous single-institution phase 11 trials.
The treatment of advanced non-small-cell lung cancer (NSCLC) continues to be a challenge to medical oncologists. Several cytotoxic drugs have been extensively investigated, either alone or in combination. As single agents, cisplatin (CDDP), ifosfamide (IFX), mitomycin-C (MMC) and vindesine (VDS) achieve a 5-20% objective response rate in chemotherapy-naive patients (Sculier, 1984; Johnson, 1990) . Recently, vinorelbine (VNR) showed interesting activity in a phase II study and in a large randomized trial (Depierre et al, 1991; Le Chevalier et al, 1994) . Combination chemotherapy induces a response rate of 20-40%, and some authors have demonstrated that three-drug cisplatin-based regimens are more active and prolong survival compared with two-drug combinations (Crin6 et al, 1995) . However, it is clear that new active combi-nations are necessary to improve the prognosis of advanced NSCLC. Unfortunately, in multicentre randomized trials, many promising regimens show an anti-tumour activity lower than that reported in single-institution phase II studies (Ardizzoni et al, 1994; Ardizzoni, 1996) . Therefore, the demonstration of a high response rate in a phase II trial is insufficient to justify the implementation of an expensive large randomized trial.
As a result of these findings, the FONICAP group has started a series of consecutive multicentre randomized phase II trials to evaluate the activity of combination regimens previously tested in singleinstitution phase II studies. The advantage of randomized phase II trials is the minimization of selection bias, which is the main cause of overestimation of response in uncontrolled phase II trials.
In the present study, three regimens were chosen: MVP (mitomycin C, vindesine, cisplatin) was chosen because it was considered to be a reference regimen (Ruckdeschel et al, 1986) ; PIN (cisplatin, ifosfamide, vinorelbine) and CaN (carboplatin, vinorelbine) had shown interesting activity in phase II trials performed at single institutions participating with the FONICAP Group (Baldini et al, 1996; Pronzato et al, 1996) .
PATIENTS AND METHODS
The eligibility criteria were as follows: histologically or cytologically proven NSCLC, stage IIIB/IV disease; no prior chemotherapy; presence of bidimensionally measurable disease; age < 75 years, World Health Organization (WHO) performance status < 2; normal haematological (haemoglobin > g dl-', white blood cell count 4000 ,.l-l and platelet count 100 000 ul-'), renal (creatinine clearance > 60 ml min-' and serum creatinine < 1.2 mg dlF') and liver (total bilirubin < 1.2 mg dl') functions.
The (Miller etal, 1981) . Patients with complete response (CR), partial response (PR) and stable disease (SD) were treated for a maximum of six courses; patients with progressive disease (PD) were withdrawn from treatment and received supportive care. Informed consent was obtained from all patients according to local institution policies.
Statistical analysis
A centralized randomization was performed by calling the FONICAP trial office at the National Institute for Cancer Research in Genoa. Allocation to each treatment arm was made using a computer-generated list stratified according to the centre.
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Simon's optimal two-stage design for phase II clinical trials was used to calculate sample size and to minimize the expected number of patients to be accrued in case of low activity combination (Simon, 1989) . Sample size was calculated on the following assumptions: alpha error = 0.05, beta error = 0.10; P0 (clinically uninteresting true response rate) and P1 (sufficiently promising true response rate), defined according to Simon, were set at 10% and 30% respectively. In the first stage, 18 patients in each arm had to be randomized: if two or less responses were observed, the accrual had to be stopped; otherwise, 17 more patients had to be accrued. The drug combination was considered of interest if seven or more responses were observed out of 35 evaluable patients. Because of the study design, a formal comparison of the three regimens was not planned.
All randomized patients were included in the final analysis of response on an 'intention to treat' basis; early deaths and early progressions were considered treatment failures.
Duration of response and survival were calculated from date of randomization; overall survival curves were plotted using the Kaplan-Meier method (Kaplan, 1958) .
RESULTS

Patient population
From August 1993 to October 1994, 140 advanced NSCLC patients entered the study. In the first step, all three regimens achieved the minimum number of responses required to proceed to the second stage. Therefore, 49 patients were randomized to receive MVP, 48 PIN and 43 CaN. The majority of the patients were men in good general conditions of health and who had stage IV disease. Patients characteristics were very similar in the three study groups (Table 1) . Out of a total of 140 randomized patients three were not eligible: two patients in the MVP arm (one SCLC and one stage IIIB because of tracheal invasion) and one patient in the PIN arm (brain metastasis).
Toxicity
Treatment toxicity was evaluable in 128 patients. Table 2 summarizes the worst toxicities per patient. Twenty patients required dose and schedule modifications because of toxicity (nine MVP, six PIN and five CaN). The main side-effect was myelosuppression: grade 3-4 leucopenia was observed in 14.3%, 25% and 18.6% of patients treated with MVP, PIN and CaN respectively. Severe nausea and vomiting were more frequently observed in patients receiving the PIN regimen. One patient receiving the PIN chemotherapy experienced a grade 4 nephrotoxicity. No severe neurotoxicity was observed. Three toxic deaths were reported: two patients receiving CaN chemotherapy died because of neutropenic fever and sepsis, and one patient being treated with PIN died because of adynamic ileus.
Activity and efficacy
Nineteen patients (MVP seven, PIN nine, CaN three) were not evaluable for response: seven patients were not evaluable because of inadequate follow-up (mostly lack of confirmation of response at 4 weeks), six because of inadequate response documentation, and six patients refused treatment. Seven early deaths (patients died before response evaluation) were reported: six patients receiving MVP and one patient receiving PIN (this patient died because of toxicity). All these patients were recorded as 'nonresponders' in the intention to treat analysis. The overall response rates, reviewed by the committee, were as follows ( (Figure 1 ).
DISCUSSION
Chemotherapy has been found to slightly improve the survival of patients with advanced NSCLC and, so far, cisplatin-containing regimens have been considered the gold standard (Stewart et al, 1995) . The PIN regimen is a new three-drug combination including cisplatin, vinorelbine and ifosfamide; ifosfamide was chosen because of its activity as a single agent and its synergism with cisplatin in experimental models (Goldin, 1982) . This regimen had shown a 60% overall response rate in a prior single-institution phase II study ; this high level of anti-tumour activity has been recently confirmed, by the same group, on a larger series of patients (Baldini et al, 1996) .
Carboplatin is a platinum analogue with non-haematological toxicity more favourable than that of the parent compound: for this reason, many phase II studies have been performed using carboplatin alone or in combination. The activity of the combination carboplatin/vinorelbine was tested in NSCLC patients with a response rate ranging from 28% to 36% in different studies, and the toxicity of the combination was generally reported as being mild (Santomaggio et al, 1994; Pronzato et al, 1996) .
In this study, all three regimens, MVP, PIN and CaN, were feasible on an outpatient basis, however their level of activity was below 30%, which was the value that had been assigned as cut-off to justify further phase III comparisons. The discrepancy between these data and those previously published might be because of several reasons: in the present randomized trial the proportion of stage IV patients was higher than those enrolled into uncontrolled phase II studies; furthermore, anti-tumour activity was calculated using an 'intention to treat' analysis, in which unevaluable patients were also included in the denominator; finally, the central review of radiological material led to the cancellation of a number of responses as judged by the investigators. Another large trial has previously reported response rates similar to those that we have observed with the MVP regimen (Einhorn et al, 1986 ).
British Journal of Cancer (1998) In conclusion, in the present study, none of the chemotherapy combinations reached the level of activity considered to be of interest to initiate a randomized phase III trial. Randomized phase II studies are a reliable and rapid method to screen the anti-tumour activity of new agents or combinations and can be used to plan the design of phase III randomized trials.
